Please ensure Javascript is enabled for purposes of website accessibility

This Company Is Disrupting Doctor's Offices

By Ryan Reeves - Jul 10, 2017 at 12:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Teladoc is a rapidly growing telehealth company that is transforming the way we interact with doctors.

Imagine if you never again had to sit in a doctor's office waiting room. A company named Teladoc (TDOC 6.13%), the largest provider of telehealth services in the nation, is trying to make that dream a reality. Telehealth is basically Facetime, but instead of a friend or a relative on the other end, it's your doctor. The company is growing rapidly, satisfying customers and strengthening its moat -- and Teladoc might be just the dose of growth your portfolio needs. 

Check-up

Teladoc is disrupting the traditional doctor's visit, with behavioral health, dermatology, and non-urgent medical matters accounting for most of telehealth traffic. No longer do patients have to call in, schedule an appointment, drive to the office, wait, wait some more, and then finally see a doctor. Teladoc's website boasts that a Member (i.e. patients using the platform) can "visit" with a doctor in less than 10 minutes from request to interaction. That's not bad, especially if the waiting room is your very own living room.

Woman speaking to a doctor on her computer

Image source: Getty Images.

The platform has been resonating with patients. Almost 1 million Members completed a telehealth visit in 2016, up from 576,000 just a year before. The number of yearly medical care visits is nearly 1.5 billion, according to Teladoc, so this could just be the beginning of a disruption to in-person medical care. 

Teladoc's revenue grew 60%, 78%, and 119% in 2016, 2015, and 2014, respectively. Teladoc has two revenue streams: subscription revenue from Clients and revenue from each visit by a Member. Interestingly, revenue from individual visits only makes up 18% of Teladoc's total revenue versus 82% from subscriptions -- meaning that the Clients are Teladoc's true target customers. Teladoc is able to reach 20.1 million Members with just 7,500 Clients.

Moat-ology

Teladoc's selling point to Clients is cost savings. A study found, on average, Clients were saved $472 per Member visit and a total of $493 million in 2016. Traditional doctor's offices need to lease buildings and cannot be quickly scaled. Similar to how retailers are struggling versus e-commerce players, telehealth providers can save costs because they have less overhead and so many suppliers (doctors in this case). 

The doctors are central to Teladoc's competitive advantage. The company currently has over 3,000 doctors signed on, and it recently acquired Best Doctors, which has 50,000 M.D.'s in its network. It will be interesting to see how well Teladoc can integrate this new pool of doctors into the platform, and this acquisition has the potential to strengthen the company's advantage immensely.   

Teladoc is not the only telehealth company out there, but it's by far the biggest -- and in this business, scale means everything. Once Clients sign on to the platform, the chances of finding a lower price are slim and so retention rates are high. As more Clients sign up, more doctors are needed, and the advantage strengthens further -- a network effect at its finest.

Health risks

The company's top dog advantage is getting stronger, but there are some risks involved.

  • First, Teladoc has acquired its way to the top, mostly by selling shares -- and such dilution waters down returns for existing investors. Teladoc already corners 75% of the market and has three times the market share of its next three competitors combined. New acquisitions would likely add little to the company's might, and they could be downright dangerous if they require even more dilution.
  • As mentioned, Teladoc is not yet profitable, even on an operating cash flow basis. If Teladoc starts losing Clients to competition or sub-par service, having negative cash flow will only exacerbate any mishaps.  
  • Lastly, the company's rapid growth has led to a premium valuation. Teladoc trades for over 13 times the trailing twelve months' revenue, a hefty price to pay. 

Prognosis

Though telehealth is a promising industry and Teladoc is growing rapidly, the stock is not fool-proof. This company is a highflier and not for the faint of heart. I wouldn't want you to have to use Teladoc's platform to treat your anxiety because of the stock's volatility! Seeing the big picture here is important though. If Teladoc can continue to sign on Clients, the future looks mighty healthy.

Ryan Reeves has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$40.32 (6.13%) $2.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.